Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent ...

BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...

Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s decision to move the asset into phase 3 studies this quarter.

Roche’s Genentech plans to start its Phase 3 this quarter, but primary completion will happen by 2028. Click here to find out ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...

However, concerns about the impact of rapid glycemic control on diabetic retinopathy risk ...

The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) to evaluate weekly ribupatide ...

The new 12-month project extends a prior two-year award for which Habegger studied mechanisms of glucagon, Glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) and ...

Roche reports positive phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity: Basel Wednesday, January 28, 2026, 10:00 Hrs [IST] Roche anno ...

In today’s Pharmaceutical Executive Daily, Roche reports positive Phase II results for a dual GLP-1/GIP receptor agonist, ...

Application error: a client-side exception has occurred (see the browser console for more information).